Ueda Motohiro, Uchimura Kohei, Ohkoshi Kie, Saegusa Natsumi, Osano Keiichi, Yoshida Shun, Konishi Makiko, Ishii Toshihisa, Takahashi Kazuya, Nakashima Ayumu
Department of Nephrology, Graduate School of Medicine, University of Yamanashi, Japan.
Intern Med. 2025 May 15;64(10):1547-1551. doi: 10.2169/internalmedicine.4835-24. Epub 2025 Mar 15.
A 60-year-old man who developed rhabdomyolysis and severe acute kidney injury (AKI) after the fourth coronavirus disease 2019 mRNA vaccination, necessitating renal replacement therapy (RRT). The patient presented to the hospital two days post-vaccination with muscle pain in both lower extremities and anuria. Diagnostic tests revealed elevated creatinine kinase (CK) levels of 160,000 IU/L and serum creatinine levels of 6.59 mg/dL, confirming AKI due to rhabdomyolysis. Intravenous therapy was ineffective, leading to the utilization of online hemodiafiltration. Following treatment, CK levels normalized, and the renal function fully recovered.
一名60岁男性在接种第四剂2019冠状病毒病mRNA疫苗后发生横纹肌溶解和严重急性肾损伤(AKI),需要进行肾脏替代治疗(RRT)。患者在接种疫苗两天后因双下肢肌肉疼痛和无尿入院。诊断检查显示肌酸激酶(CK)水平升高至160,000 IU/L,血清肌酐水平为6.59 mg/dL,确诊为横纹肌溶解所致的AKI。静脉治疗无效,遂采用在线血液透析滤过治疗。治疗后,CK水平恢复正常,肾功能完全恢复。